Endeavor BioMedicines

涉及Endeavor BioMedicines的并购和融资。

• Endeavor BioMedicines 刚刚宣布为 132 筹款数百万美元。 (公布2024四月25号).

查看带有其 15 名主要高管的组织结构图

Endeavor BioMedicines 搜索最多的简介

• John Hood, Chief Executive Officer and Director
• Andrew Lam, Director
• Noelle Hutchins, Director

高管在Endeavor BioMedicines变化

• Chris Krueger已作为Chief Operating Officer加入公司  (新闻发布的2024四月17号).
• Vishaal Turakhia已作为Chief Financial Officer加入公司  (新闻发布的2024三月15号).
• Enoch Kariuki 曾任 Director, 现升职为 President  (新闻发布的2024三月15号).

更多的变化在％s

创建提醒
跟踪 Endeavor BioMedicines 的高管变动

Endeavor BioMedicines 拥有 2,287 家竞争者，其中包括 Lonza (瑞士)、Eurofins (卢森堡) 和 Adaptive Phage Therapeutics (美国(美洲))。

Popular M&A news in 生物技术

• Delphia Therapeutics 刚刚宣布为 67 筹款数百万美元。 (公布2024五月7号).
• Karius 刚刚宣布为 100 筹款数百万美元。 (公布2024五月3号).
• Transcarent 刚刚宣布为 126 筹款数百万美元。 (公布2024五月2号).

生物技术 行业的其他推荐联系人

• Adaptimmune Therapeutics 企业 Ali Behbahani - Non-Executive Director
• Sensorion 企业 Khalil Barrage - Interim Chairman of the Board
• Interline Therapeutics 企业 Vik Bajaj - Director

了解更多有关生物技术行业的信息 >

Endeavor BioMedicines 的最新新闻稿

• Media Coverage | Endeavor BioMedicines
• Endeavor BioMedicines Appoints Enoch Kariuki, Pharm.D. as President and Vishaal Turakhia as Chief Financial Officer | Endeavor Biomedicines
• Endeavor BioMedicines Successfully Completes Phase 2a Trial of ENV-101 in Patients with Idiopathic Pulmonary Fibrosis | Endeavor Biomedicines
• Endeavor BioMedicines Appoints Enoch Kariuki, Pharm.D. to Board of Directors | Endeavor Biomedicines
• Endeavor BioMedicines Appoints Paul Frohna, M.D., Ph.D., as Chief Medical Officer | Endeavor Biomedicines
• Endeavor BioMedicines Enters License Agreement with Hummingbird Bioscience for Worldwide Rights to HMBD-501, a Next Generation HER3-Targeted Antibody-Drug Conjugate (ADC) | Endeavor Biomedicines
• Endeavor Launches With $62m And A Hedgehog Inhibitor From Lilly
• Endeavor BioMedicines Closes $101M Series B Financing to Advance Clinical-Stage Precision Medicine Pipeline | Endeavor Biomedicines
• Endeavor BioMedicines Completes Enrollment in Phase 2a Clinical Trial of ENV-101 (Taladegib) for the Treatment of Idiopathic Pulmonary Fibrosis (IPF) | Endeavor Biomedicines
• Endeavor BioMedicines Partners with xCures to Identify Patients with PTCH1 mutations for Phase 2 Trial of ENV-101 (taladegib) | Endeavor Biomedicines
• View more press releases Close

关于 Endeavor BioMedicines 的社交媒体

• Endeavor BioMedicines 在 维基百科、谷歌新闻 和 雅虎财经
• Endeavor BioMedicines 在 LinkedIn、叽叽喳喳 和 YouTube

通过电子邮件联系联系该企业高管，包括 Bernard Davitian

致电Endeavor BioMedicines，电话：+1 858...

查看组织结构图

Register to receive your alert

报告错误